HIGHLIGHTS   |  May 22, 2020   David S. Hong, MD, on Outcomes of Larotrectinib in Patients with TRK Fusion Cancer The medical oncologist discussed reported outcomes of larotrectinib in patients with TRK fusion cancer by the number of lines of priory therapy or baseline status. Read more   Initiation of Adjuvant Therapy Within 3 Weeks After Surgical Resection of GBM Could Be Detrimental Recent data suggests that, while short delays beyond 5 weeks after surgical resection of glioblastoma did not negatively impact survival outcomes, early initiation of chemoradiation before 3 weeks could be detrimental to patients. Read more   In Case You Missed It

Continued Treatment with SGX301 in Patients with CTCL Increases Response Rates SGX301 is being evaluated for the treatment of patients with early-stage cutaneous T-cell lymphoma in the pivotal phase III FLASH study, which demonstrated that continued treatment twice weekly for 12 weeks increased the positive response rate. Read more